Skip to main content
ROSSARI BIOTECH LIMITED logo

ROSSARI BIOTECH LIMITED — Investor Relations & Filings

Ticker · ROSSARI ISIN · INE02A801020 LEI · 335800R7XFRR8ZTHBQ25 BSE.NS Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS ROSSARI

About ROSSARI BIOTECH LIMITED

https://www.rossari.com/

Rossari Biotech Limited is a specialty chemicals manufacturer focused on providing sustainable and innovative solutions across diverse sectors. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition. In the HPPC segment, it supplies essential ingredients for detergents, soaps, paints, and water treatment applications. Its textile division offers a comprehensive range of chemicals for the entire textile value chain, including pre-treatment, dyeing, and finishing processes. Additionally, the company provides high-quality feed additives and supplements for the poultry and livestock industries. Driven by robust research and development capabilities, Rossari Biotech emphasizes eco-friendly chemistry and customized formulations to meet specific client requirements. With advanced manufacturing facilities, the company serves a global clientele, maintaining a strong focus on operational excellence.

Recent filings

Filing Released Lang Actions
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Regulatory Filings Classification · 85% confidence The document is a continuous disclosure made under Regulation 30 of SEBI’s Listing Regulations to BSE and NSE regarding the completion of a sale of office premises by a material subsidiary. It is not the report itself but a regulatory announcement of a material event. It does not fit into more specific categories such as financing, M&A, dividend, or share issue. Therefore, it is classified as a general regulatory filing.
2026-05-21 English
Agreements
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations (Regulation 30) providing details of a sale transaction by a subsidiary. It is a material event disclosure to stock exchanges rather than a full financial report, a management presentation, a dividend notice, M&A brochure, or any other specialized category. It does not include substantive financial statements or analysis, nor is it a management/earnings call transcript, proxy, or annual report. It therefore falls under the general “Regulatory Filings” category as a catch-all for compliance announcements.
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Rossari Biotech Limited covering Q4 and FY26 financial results. It includes management commentary on financial performance, operational highlights, strategic initiatives, and a Q&A session with analysts. The presence of detailed financial figures, discussion of quarterly and full-year results, and forward-looking statements typical of earnings calls confirms this classification. The document is not a brief announcement, regulatory filing, or presentation but a full transcript of the earnings call.
2026-05-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of the audio recording of an earnings conference call for Q4 FY26. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosures related to events like earnings calls. The document does not contain any financial data or detailed transcript but only informs about the availability of the audio recording on the company's website. The document length is short (2240 characters), and it is an announcement about the earnings call recording, not the call transcript itself. Therefore, it should be classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit the full call transcript (CT) category or earnings release (ER) category which would contain financial highlights or data.
2026-04-28 English
Cessation
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the completion of tenure of Ms. Aparna Sharma as an Independent Director of Rossari Biotech Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The content includes details about the cessation of directorship, committee memberships, and related disclosures. There is no financial data, earnings information, or report publication mentioned. The document is clearly about a change in the company's board of directors, specifically the end of an independent director's term. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 4939 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2026-04-28 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Q4 & FY26 Earnings Presentation' and contains detailed financial highlights for the quarter and full fiscal year ended March 31, 2026. It includes consolidated P&L statements, balance sheets, cash flow statements, management commentary, and key developments. The content is a detailed presentation of quarterly and annual financial results, including operational and strategic updates. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not a brief earnings release (ER) since it contains extensive data and commentary, nor is it an Annual Report (10-K) or Interim Report (IR) as it is specifically a presentation document. Therefore, the correct classification is Investor Presentation (IP).
2026-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.